Patent intelligence · US
US 8211428
Protease screening methods and proteases identified thereby
Protease screening methods and proteases identified thereby
Patent details — US 8211428
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 3, 2012
- Expiration
- Jun 28, 2032
- Applicant
- Catalyst Biosciences, Inc.
- Claims
- 59
- CPC classes
- A61K, A61K38/00, A61P, A61P1/00
Quick answer
US 8211428 (Protease screening methods and proteases identified thereby) is held by Catalyst Biosciences, Inc.. Status: granted. Granted Jul 3, 2012. Expires Jun 28, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Catalyst Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 59
- CPC classes
- A61K, A61K38/00, A61P, A61P1/00, A61P1/02, A61P1/04
More from Catalyst Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11701307
Organic-inorganic composite particles, manufacturing method therefor, and cosmetic
granted -
US 11491212
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
granted -
US 11401513
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11266724
Modified factor VII polypeptides for subcutaneous administration and on-demand treatment
granted -
US 11203749
Factor VII polypeptides that are modified and uses thereof
granted -
US 11020326
Hollow particles and cosmetic
granted
Frequently asked questions
What is US patent 8211428?
US 8211428 (Protease screening methods and proteases identified thereby) is held by Catalyst Biosciences, Inc.. Status: granted. Granted Jul 3, 2012. Expires Jun 28, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8211428?
Catalyst Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 61 pharmaceutical patents for this assignee.
When does US 8211428 expire?
Our index shows an expiration date of Jun 28, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.